MDGL

MDGL

USD

Madrigal Pharmaceuticals Inc. Common Stock

$489.260+1.230 (0.252%)

即時價格

Healthcare
生物科技
美國

價格圖表

Loading Chart...

關鍵指標

市場指標
公司基本面
交易統計

市場指標

開盤

$488.030

最高

$494.550

最低

$477.000

交易量

0.76M

公司基本面

市值

11.1B

行業

生物科技

國家

United States

交易統計

平均交易量

0.37M

交易所

NMS

貨幣

USD

52週範圍

最低 $265當前 $489.260最高 $496.98

相關新聞

Analyst Upgrades

B of A Securities Upgrades Madrigal Pharmaceuticals to Neutral, Raises Price Target to $445

B of A Securities analyst Alexandria Hammond upgrades Madrigal Pharmaceuticals from Underperform to Neutral and raises the price target from $266 to $445.

查看更多
B of A Securities Upgrades Madrigal Pharmaceuticals to Neutral, Raises Price Target to $445
GlobeNewswire

Madrigal to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025

Two oral presentations to highlight biomarker, imaging and quality-of-life data from the open-label compensated MASH cirrhosis (F4c) arm of the Phase 3 MAESTRO-NAFLD-1 trial of RezdiffraPoster of distinction examines the

查看更多
Madrigal to Present New Data from the Company's MASH Program at AASLD's The Liver Meeting 2025
GlobeNewswire

Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)

CONSHOHOCKEN, Pa., Oct. 21, 2025 (GLOBE NEWSWIRE) -- Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated

查看更多
Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4)
Analyst Upgrades

Truist Securities Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $580

Truist Securities analyst Srikripa Devarakonda initiates coverage on Madrigal Pharmaceuticals with a Buy rating and announces Price Target of $580.

查看更多
Truist Securities Initiates Coverage On Madrigal Pharmaceuticals with Buy Rating, Announces Price Target of $580